Emergency: 911
Telecare: 811
Poison: 1-800-565-8161
5850/5980 University Ave., Halifax, NS B3K 6R8

Children with BPD/CLD: Palivizumab (Synagis®)

Updated November 2022

Seasonal administration of palivizumab should be considered for children <24 months of age with bronchopulmonary dysplasia (BPD) / chronic lung disease (CLD) and who have required oxygen within 6 months preceding the RSV season (i.e. June 1st - November 2022), or other pulmonary disorders requiring oxygen therapy (e.g. hypoplastic lung).